Show simple item record

dc.contributor.authorGarrison, Garth W
dc.contributor.authorCho, Josalyn L
dc.contributor.authorDeng, Jane C
dc.contributor.authorCamac, Erin
dc.contributor.authorOh, Scott
dc.contributor.authorSundar, Krishna
dc.contributor.authorBaptiste, Janelle V
dc.contributor.authorCheng, Guang-Shing
dc.contributor.authorDe Cardenas, Jose
dc.contributor.authorFitzgerald, Codi
dc.contributor.authorGarfield, Jamie
dc.contributor.authorHa, Ngoc-Tram
dc.contributor.authorHolden, Van K
dc.contributor.authorO'Corragain, Oisin
dc.contributor.authorPatel, Sahil
dc.contributor.authorWayne, Max T
dc.contributor.authorMcSparron, Jakob I
dc.contributor.authorWang, Tisha
dc.contributor.authorÇoruh, Başak
dc.contributor.authorHayes, Margaret M
dc.contributor.authorGuzman, Elizabeth
dc.contributor.authorChannick, Colleen L
dc.date.accessioned2021-10-22T15:54:56Z
dc.date.available2021-10-22T15:54:56Z
dc.date.issued2021-09-01
dc.identifier.urihttp://hdl.handle.net/10713/16919
dc.description.abstractThe American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine at the annual international conference. The 2021 Pulmonary Core Curriculum focuses on lung cancer and include risks and prevention, screening, nodules, therapeutics and associated pulmonary toxicities, and malignant pleural effusions. Although tobacco smoking remains the primary risk factor for developing lung cancer, exposure to other environmental and occupational substances, including asbestos, radon, and burned biomass, contribute to the global burden of disease. Randomized studies have demonstrated that routine screening of high-risk smokers with low-dose chest computed tomography results in detection at an earlier stage and reduction in lung cancer mortality. On the basis of these trials and other lung cancer risk tools, screening recommendations have been developed. When evaluating lung nodules, clinical and radiographic features are used to estimate the probability of cancer. Management guidelines take into account the nodule size and cancer risk estimates to provide recommendations at evaluation. Newer lung cancer therapies, including immune checkpoint inhibitors and molecular therapies, cause pulmonary toxicity more frequently than conventional chemotherapy. Treatment-related toxicity should be suspected in patients receiving these medications who present with respiratory symptoms. Evaluation is aimed at excluding other etiologies, and treatment is based on the severity of symptoms. Malignant pleural effusions can be debilitating. The diagnosis is made by using simple pleural drainage and/or pleural biopsies. Management depends on the clinical scenario and the patient's preferences and includes the use of serial thoracentesis, a tunneled pleural catheter, or pleurodesis.en_US
dc.description.urihttps://doi.org/10.34197/ats-scholar.2021-0032REen_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8518653/en_US
dc.language.isoenen_US
dc.publisherAmerican Thoracic Societyen_US
dc.relation.ispartofATS Scholaren_US
dc.rightsCopyright © 2021 by the American Thoracic Society.en_US
dc.subjectlung cancer risksen_US
dc.subjectlung cancer screeningen_US
dc.subjectlung cancer treatment toxicityen_US
dc.subjectlung noduleen_US
dc.subjectmalignant effusionen_US
dc.titleATS Core Curriculum 2021. Adult Pulmonary Medicine: Thoracic Oncologyen_US
dc.typeArticleen_US
dc.identifier.doi10.34197/ats-scholar.2021-0032RE
dc.identifier.pmid34667994
dc.source.volume2
dc.source.issue3
dc.source.beginpage468
dc.source.endpage483
dc.identifier.eissn2690-7097
dc.source.countryUnited States
dc.identifier.journalATS scholar


This item appears in the following Collection(s)

Show simple item record